Surveillance reports anaphylaxis cases after first Moderna COVID-19 vaccine doses in US

A surveillance report from the United States describes a case series of individuals who experienced allergic reactions, including anaphylaxis, after receiving their first dose of the Moderna COVID-19 vaccine. The report documents the occurrence of these serious adverse events but does not provide the sample size, absolute number of cases, or an estimated incidence rate. No comparator group or follow-up duration was reported.

The primary outcome was cases of anaphylaxis. The result was that cases were reported; however, no effect size, p-values, confidence intervals, or direction of association were provided. Secondary outcomes were not specified. The safety data specifically note anaphylaxis as a serious adverse event, but tolerability and discontinuation rates were not reported.

Key limitations include the observational nature of surveillance data, the absence of a control group, and the lack of a calculated incidence rate. The authors report a temporal association but explicitly note causation is not established. Funding and conflicts of interest were not reported. For practice, this report signals the need for continued post-marketing surveillance and preparedness to manage acute allergic reactions, but it does not provide data to quantify risk or compare it to other vaccines.